Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)
Stonegate Capital Partners has initiated coverage on Incannex Healthcare Inc. (NASDAQ: IXHL), a company focused on developing proprietary, synthetic first and best-in-class cannabinoid and psychedelic-assisted therapeutics. The key highlights of the coverage include:
1. Incannex is currently conducting an FDA phase 2/3 trial for IHL-42X, targeting the treatment of Obstructive Sleep Apnea (OSA).
2. The company expects to release top-line data from the pivotal phase 2 trial of IHL-42X in the first half of 2025.
This coverage initiation by Stonegate Capital Partners suggests increased attention on Incannex's innovative therapeutic approaches and ongoing clinical trials in the cannabinoid and psychedelic-assisted treatment space.
Stonegate Capital Partners ha avviato la copertura su Incannex Healthcare Inc. (NASDAQ: IXHL), un'azienda focalizzata nello sviluppo di terapie proprietarie sintetiche di prima classe nel campo dei cannabinoidi e dei trattamenti assistiti da psichedelici. I principali punti salienti di questa copertura includono:
1. Incannex sta attualmente conducendo un trial FDA di fase 2/3 per IHL-42X, mirato al trattamento dell'Apnea Ostruttiva del Sonno (OSA).
2. L'azienda prevede di rilasciare i dati preliminari del trial cruciale di fase 2 di IHL-42X nella prima metà del 2025.
Questa iniziativa di copertura da parte di Stonegate Capital Partners suggerisce un'attenzione crescente verso gli approcci terapeutici innovativi di Incannex e i trial clinici in corso nel campo del trattamento assistito da cannabinoidi e psichedelici.
Stonegate Capital Partners ha iniciado la cobertura de Incannex Healthcare Inc. (NASDAQ: IXHL), una compañía enfocada en desarrollar terapias sintéticas innovadoras y de primera clase basadas en cannabinoides y asistidas por psicodélicos. Los puntos clave de esta cobertura incluyen:
1. Incannex está llevando a cabo actualmente un ensayo de fase 2/3 de la FDA para IHL-42X, dirigido al tratamiento de la Apnea Obstructiva del Sueño (OSA).
2. La compañía espera publicar los datos preliminares del ensayo pivotal de fase 2 de IHL-42X en la primera mitad de 2025.
Esta iniciación de cobertura por parte de Stonegate Capital Partners sugiere una mayor atención hacia los enfoques terapéuticos innovadores de Incannex y los ensayos clínicos en curso en el ámbito del tratamiento asistido por cannabinoides y psicodélicos.
Stonegate Capital Partners는 Incannex Healthcare Inc. (NASDAQ: IXHL)에 대한 커버리지를 시작했습니다. 이 회사는 독점적이고 합성된 최고 급의 카나비노이드 및 환각제 보조 치료제를 개발하는 데 주력하고 있습니다. 이번 커버리지의 주요 하이라이트는 다음과 같습니다:
1. Incannex는 현재 IHL-42X에 대한 FDA 2/3상 시험을 진행 중이며, 이는 폐쇄성 수면 무호흡증 (OSA) 치료를 목표로 하고 있습니다.
2. 이 회사는 2025년 상반기 중 IHL-42X의 중요한 2상 시험 결과를 발표할 예정입니다.
Stonegate Capital Partners의 이번 커버리지 시작은 Incannex의 혁신적인 치료 접근 방식과 카나비노이드 및 환각제 보조 치료 분야에서 진행 중인 임상 시험에 대한 관심이 높아지고 있음을 시사합니다.
Stonegate Capital Partners a lancé la couverture de Incannex Healthcare Inc. (NASDAQ: IXHL), une entreprise axée sur le développement de thérapies synthétiques propriétaires, de premier plan et de classe mondiale dans le domaine des cannabinoïdes et des traitements assistés par des psychédéliques. Les points clés de cette couverture incluent :
1. Incannex mène actuellement un essai de phase 2/3 de la FDA pour IHL-42X, visant à traiter l'
2. L'entreprise s'attend à publier les données préliminaires de l'essai pivot de phase 2 de IHL-42X au cours de la première moitié de 2025.
Cette initiation de couverture par Stonegate Capital Partners indique une attention accrue portée aux approches thérapeutiques innovantes d'Incannex et aux essais cliniques en cours dans le domaine des traitements assistés par les cannabinoïdes et les psychédéliques.
Stonegate Capital Partners hat die Berichterstattung über Incannex Healthcare Inc. (NASDAQ: IXHL) aufgenommen, ein Unternehmen, das sich auf die Entwicklung proprietärer, synthetischer, erstklassiger cannabinoid- und psychedelisch unterstützter Therapeutika konzentriert. Die wichtigsten Punkte der Berichterstattung sind:
1. Incannex führt derzeit eine FDA Phase 2/3 Studie für IHL-42X durch, die auf die Behandlung von obstruktiver Schlafapnoe (OSA) abzielt.
2. Das Unternehmen plant, in der ersten Jahreshälfte 2025 die Daten der entscheidenden Phase 2 Studie von IHL-42X zu veröffentlichen.
Diese Aufnahme der Berichterstattung durch Stonegate Capital Partners deutet auf ein erhöhtes Interesse an den innovativen therapeutischen Ansätzen von Incannex und den laufenden klinischen Studien im Bereich der cannabinoid- und psychedelisch unterstützten Behandlung hin.
- Stonegate Capital Partners initiates coverage, potentially increasing visibility for IXHL
- Ongoing FDA phase 2/3 trial for IHL-42X in treating Obstructive Sleep Apnea
- Pivotal phase 2 top-line data for IHL-42X expected in first half 2025
- None.
Dallas, Texas--(Newsfile Corp. - October 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners initiates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL)
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Advancing proprietary, synthetic first and best-in-class cannabinoid and psychedelic-assisted therapeutics
- Conducting FDA phase 2/3 trial, IHL-42X, for the treatment of Obstructive Sleep Apnea (OSA)
- IHL-42X pivotal phase 2 top-line data expected first half 2025
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/225397
FAQ
What is the focus of Incannex Healthcare Inc. (IXHL)?
What clinical trial is Incannex Healthcare (IXHL) currently conducting?
When does Incannex Healthcare (IXHL) expect to release top-line data for the IHL-42X trial?
Which firm initiated coverage on Incannex Healthcare (IXHL) in October 2024?
